ReviewAvicenna journal of phytomedicine2026
A systematic review of the biological effects of resveratrol on venous thromboembolism.
Review in Avicenna journal of phytomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Venous thromboembolism (VTE) has high morbidity in major surgery, serious injury, or during periods of inflammation and infection. VTE has serious complications, resulting in death. This review aims to evaluate the efficacy and mechanisms of resveratrol (RSV) in preventing and treating deep vein thrombosis (DVT) and pulmonary embolism (PE). Material and methods: Various databases like MEDLINE/PubMed, Embase, Scopus, Cochrane Library, and Web of Science were comprehensively searched to find relevant studies published before January 2024. After defining the inclusion and exclusion criteria, selecting studies related to the purpose of the study, data were extracted, and study characteristics, methods, and biological mechanisms were recorded and reviewed. Results: RSV potentially prevents and attenuates VTE through antioxidant, anti-inflammatory, and anticoagulant mechanisms. It inhibited endothelial and platelet reactive oxygen species (ROS) production, enhanced endogenous antioxidants, and downregulated nuclear factor kappa B (NF-κB) and proinflammatory cytokines. RSV also regulated coagulation and fibrinolysis, inhibited tissue factor (TF) and myeloperoxidase (MPO), and reduced apoptosis. Additionally, RSV reduced adhesion molecule expression, including vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule 1 (ICAM-1), P-selectin, and von Willebrand Factor (vWF), while promoting vasodilation and endothelial protection through increased nitric oxide (NO) production, SIRT1 activation, and ANGPT2 expression. Conclusion:
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.